Guggenheim analyst Yatin Suneja downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with an $8 price target after the company agreed to be acquired by Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Market Perform from Outperform at William Blair
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
- Vigil Neuroscience Inc trading halted, news pending
- Vigil Neuroscience Advances Clinical Trials and Financial Stability